ABC | Volume 110, Nº2, February 2018

Original Article Lorenzo et al Clinical characterization of patients with HF Arq Bras Cardiol. 2018; 110(2):119-123 Table 1 – Demographic, anthropometric and clinical characteristics of patients with positive or negative genetic testing for familial hypercholesterolemia Positive (n = 15) Negative (n = 30) p-value Age (years) 51.7 ± 14.4 55.6 ± 12.6 0.376 Weight 71.4 ± 16.1 70.8 ± 15.7 0.906 Body mass index (Kg/m²) 27.9 ± 6.1 28.3 ± 5.1 0.784 Body fat (%) 39.1 ± 9.4 35.6 ± 8.2 0.262 Visceral fat area (cm²) 110.3 ± 34.0 104.6 ± 34.3 0.639 Waist circumference (cm) 95.6 ± 10.6 96.5 ± 11.9 0.589 Hip circumference (cm) 104.4 ± 11.6 102.8 ± 12.1 0.676 Women 14 (93.3) 18 (60.0) 0.019* Clinically defined FH 10 (66.7) 4 (13.3) 0.001* Score 9.64 ± 2.16 4.35 ± 1.58 0.001* Risk factors and clinical data Hypertension 8 (53.3) 20 (71.4) 0.197 Diabetes 3 (20.0) 6 (21.4) 0.619 Obesity 7 (46.7) 9 (30.0) 0.219 Smoking 0 3 (10.7) 0.265 Corneal arch 3 (20.0) 1 (3.7) 0.122 Xanthomata 0 0 Xanthelasma 3 (20.0) 0 (0) 0.04* Angina 6 (40.0) 12 (42.0) 0.559 History of stroke 0 (0) 1 (3.6) 0.651 History of myocardial infarction 3 (20.0) 11 (39.3) 0.173 Prior coronary angioplasty 3 (20.0) 11 (40.7) 0.153 Prior coronary bypass 4 (26.7) 5 (17.9) 0.381 Numbers are n (%), for categorical variables, or mean ± SD, for continuous variables; (*) p < 0.05; FH: familial hypercholesterolemia. Table 2 – Laboratory data of patients with positive or negative genetic testing for familial hypercholesterolemia Positive (n = 15) Negativo (n = 30) p-value Total cholesterol (mg/dL) 263.1 ± 93.1 231.0 ± 57.4 0.417 LDL-C (mg/dL) 208.1 ± 41.8 151.4 ± 50.6 0.002* HDL-C (mg/dl) 52.2 ± 9.7 50.1 ± 12.0 0.617 Apo A1 (mg/dL) 139.3 ± 19.9 140.1 ± 22.9 0.916 Apo B (mg/dL) 138.7 ± 30,2 106.3 ± 31.6 0.005* Triglyceride (mg/dL) 127.9 ± 52.1 144.6 ± 73.5 0.484 CRP (mg/dL) 0.4 ± 0.7 0.3 ± 0.6 0.707 Glycemia (mg/dL) 116.4 ± 79.9 107.5 ± 48,2 0.667 Numbers are n (%), for categorical variables, or mean ± SD, for continuous variables; (*) p < 0.05;ApoA1: apolipoproteinA1;Apo B: apolipoprotein B; CRP-C: reactive protein; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol. However, when patients were stratified according to genetic testing positivity, those with any of the studied mutations did not show any correlation between LDL-C and other variables, while for those without a mutation, there was a moderate, statistically significant correlation between LDL-C and the clinical point score (R = 0.554, p = 0.01), as well as a borderline significant, moderate correlation between LDL-C and body fat (R = 0.441, p = 0.05). 121